Where does Moderna Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Moderna Therapeutics, Inc. ranks #10,688 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Moderna Therapeutics, Inc. hold?

Moderna Therapeutics, Inc. holds 29 US utility patents granted between 2015 and 2017, spanning 9 technology areas.

What is Moderna Therapeutics, Inc.'s Innovation Score?

Moderna Therapeutics, Inc. has an Innovation Score of 30.6 out of 100 (35th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Moderna Therapeutics, Inc. focus on?

Moderna Therapeutics, Inc.'s top technology area is C07K (Peptides) with 29 patents, ranking #328 of 3,615 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Moderna Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Moderna Therapeutics, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Moderna Therapeutics, Inc.'s patents?

Moderna Therapeutics, Inc.'s patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Moderna Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Moderna Therapeutics, Inc.

USPTO PatentsView assignee record - 29 granted patents across 9 technology areas, recorded in grant years 2015–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Moderna ranks #10,688 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 9 technology areas.

#10,688
of 49,997 US assignees by volume: 35th percentile
by Innovation Score (30.6/100): 13.8
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10688 · US Corporation #10,688 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,688/49,997
PHOTO-FINISH MedTech
CPC-NARROW C07K · 9 areas
INNOV-THIN 30.6/100
CLAIMS-RICH 13.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: MedTech S.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Moderna’s 30.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (38%) Velocity 0.0 pts (0%) Breadth 10.6 pts (35%) Claim depth 8.3 pts (27%)

Qualcomm Incorporated · highest

85
Rimowa · near

31
Spyderco · near

31
Linde Engineering… · near

31
Moderna Therapeutics · this assignee

31
ORTHOsoft · near

31
3D Lighting… · lowest

7

What this shows Moderna's Innovation Score is 30.6/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Moderna?

Each dot is one of Moderna’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Moderna’s own 13.8 claims/patent is ABOVE the 13.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Moderna vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Moderna's grants concentrate

Moderna Therapeutics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (16 grants) versus a trough of 1 in 2017. By volume, Moderna sits between MeMed Diagnostics Ltd. and Myriad Genetics, Inc..

Memed Diagnostics

29
Medtech

29
Micell

29
Mississippi Lime

29
Moraine

29
Moshun

29
Movellus Circuits

29
Myriad Genetics

29
Moderna Therapeut… ◀

29

What this shows Moderna holds 29 patents at rank #10,690, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Moderna

By rank, the assignees closest to #10,690 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Moderna's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Moderna, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Moderna ranks #328 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (31 here).

ORTHOsoft, Inc. 31 Linde Engineering North America, Inc. 31 Spyderco, Inc. 31 Rimowa GmbH 31

Moderna's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 35th percentile higher than 35% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2017

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Moderna Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	16	55.2%
2016	12	41.4%
2017	1	3.4%

Which technologies does Moderna Therapeutics, Inc. patent most?

C07K - Peptides 29

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 29

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 26

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 23

C12Y - Enzymes 22

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 19

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 14

Y02A - Technologies FOR Adaptation TO Climate Change 12

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Moderna Therapeutics, Inc.'s patent record in context - here's where to go next.

Moderna Therapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #10,688 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Moderna Therapeutics, Inc. against MeMed Diagnostics Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.